PAGBAM assists in BCA of APx, OmnigenicsAI and MultiplAI Health
Pérez Alati Grondona Benites & Arntsen has assisted APx Acquisition Corp, in Argentina, in the signing of a business combination agreement (BCA) with OmnigenicsAI Corp and MultiplAI Health for the creation of a global AI-based genomics platform.
APx is a publicly traded special purpose acquisition company while OmigenincsAI is a precision medicine company incubated by Bioceres Group and MultiplAI is a UK-based AI-based preventive medicine company.
The BCA resulted in the creation of a global genomics company, whose shares will be publicly traded and will use artificial intelligence (AI) to advance the field of precision medicine.
Greenberg Traurig, Maples & Calder (Cayman) also advised APx; while Linklaters, Ogier and Marval O’Farrell & Mairal advised OmnigenicsAI.
PAGBAM’s team was led by the corporate team, comprising partner P. Eugenio Aramburu (pictured left) and associates Nicolás del Campo Wilson and Azul María Juárez Pereyra, supported by the antitrust team comprising partner Luis D. Barry (pictured right) and counsel M. Clara Rodríguez Llanos and data privacy team by counsel Pia Politi.
